Welcome to our dedicated page for Compugen SEC filings (Ticker: CGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compugen Ltd. files foreign-issuer reports that document its clinical-stage cancer immunotherapy business, financial results and material corporate developments. Its Form 6-K filings cover quarterly and annual results, interim consolidated financial statements, management discussion and analysis, Inline XBRL financial data, and corporate updates related to programs such as COM701, COM902, rilvegostomig and GS-0321.
The filing record also documents licensing and royalty arrangements, including amendments to the AstraZeneca rilvegostomig agreement, as well as proxy materials, annual general meeting voting results, board composition and registration-statement incorporation matters under Form F-3. These disclosures frame Compugen's capital resources, collaboration economics, governance actions, clinical-development disclosures and foreign private issuer reporting obligations.
Ophir Eran submitted a Form 144 notice to sell 5,000 Ordinary shares of the issuer tied to an Employee Stock Option Plan, with the filing date shown as 04/14/2026. The record shows prior sales of 5,626 Ordinary shares on 04/01/2026 with an amount listed as 12412.68.
CGEN submitted a Rule 144 notice reporting an intended sale of 2,000 ordinary shares under an Employee Stock Options plan, with the sale dated 04/14/2026 and listed as Cash - Upon Exercise. The filing also lists a prior sale of 26,375 shares on 03/26/2026 generating $58,657.50.
Compugen Ltd. senior vice president Zurit Levine exercised share options and sold shares in a planned transaction. On April 10, 2026, she exercised options for a total of 3,125 Ordinary Shares at strike prices of $0.8292 and $1.15 per share, then sold 3,125 Ordinary Shares at a weighted average price of $2.564 per share under a Rule 10b5-1 trading plan. Following these transactions, she holds 29,375 Ordinary Shares directly and retains share option positions totaling 5,625 and 56,000 options, respectively.
Levine Zurit reported a sale of 24,375 Ordinary Shares on 03/26/2026 for $53,457.50. The filing also lists 2,000 Ordinary Shares tied to an Employee Stock Options plan that are noted for cash upon exercise with an associated date of 04/10/2026. The broker listed is Oppenheimer & Co. Inc. and shares outstanding are shown as 94,553,191 as of 04/10/2026.
Compugen Ltd senior vice president of business development Zurit Levine reported a series of option exercises and share sales. On April 7–8, 2026, Levine exercised share options for a total of 7,875 Ordinary Shares at exercise prices of $0.8292 and $1.15, then sold 7,875 Ordinary Shares in open-market transactions at prices of $2.30 and $2.42. Following these transactions, Levine directly holds 29,375 Ordinary Shares. The filing notes these trades were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025.
Compugen Ltd SVP of Business Development Zurit Levine exercised stock options and sold shares in a pre-planned transaction. On this Form 4, Levine exercised options to acquire 3,500 Ordinary Shares at exercise prices of $0.8292 and $1.15 per share, then sold 3,500 Ordinary Shares at $2.20 per share.
The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 23, 2025, indicating they were pre-arranged. After these trades, Levine directly holds 29,375 Ordinary Shares.
COMPUGEN LTD President and CEO Ophir Eran exercised stock options and sold shares in a planned transaction. On this Form 4, he exercised options to acquire 5,625 Ordinary Shares at an exercise price of $0.8292 per share, converting a derivative position into common stock. On the same date, he sold 5,625 Ordinary Shares at a weighted average price of $2.2067 per share in open-market transactions made under a Rule 10b5-1 trading plan adopted on December 26, 2025. Following these transactions, he directly holds 11,375 Ordinary Shares and 24,375 Share Options.
COMPUGEN LTD senior vice president of business development Zurit Levine exercised stock options and sold shares in a planned transaction. She exercised options for 11,875 ordinary shares at an exercise price of $0.8292 per share, then sold 11,875 ordinary shares at a weighted average price of $2.0368 per share.
The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 23, 2025, indicating it was scheduled in advance rather than timed discretionarily. Following these transactions, Levine holds 29,375 ordinary shares directly.
CGEN affiliate filed a notice to sell 24,375 ordinary shares. The filing lists two option-originated lots: 22,375 shares from an 11/09/2022 grant and 2,000 shares from an 08/03/2023 grant, with the proposed sale date of 03/26/2026. The filing lists an aggregate amount of $50,212.50 and shows 94,553,191 shares outstanding as of 03/26/2026 as context.